Progress and opportunities for immune therapeutics in osteosarcoma

被引：60

作者：

Lettieri, Christina K. ^{[1
]}

Appel, Nicole ^{[2
]}

Labban, Nicole ^{[2
]}

Lussier, Danielle M. ^{[2
]}

Blattman, Joseph N. ^{[2
]}

Hingorani, Pooja ^{[3
]}

机构：

[1] Childrens Hosp & Med Ctr, Omaha, NE 68198 USA

[2] Arizona State Univ, Sch Life Sci, Tempe, AZ 85281 USA

[3] Phoenix Childrens Hosp, Ctr Canc & Blood Disorders, Phoenix, AZ 85016 USA

来源：

IMMUNOTHERAPY | 2016年 / 8卷 / 10期

关键词：

clinical trials; immune checkpoint inhibitors; immune tolerance; immunotherapy; osteosarcoma; MODIFIED T-CELLS; CONJUGATE GLEMBATUMUMAB VEDOTIN; NATURAL-KILLER-CELLS; FACTOR RECEPTOR 2; MHC CLASS-I; ANTITUMOR-ACTIVITY; DENDRITIC CELLS; ESTABLISHED OSTEOSARCOMA; ADOPTIVE IMMUNOTHERAPY; ADAPTIVE IMMUNITY;

D O I：

10.2217/imt-2016-0048

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Survival outcomes for osteosarcoma have plateaued since the 1980s, and patients with relapsed or refractory disease have a particularly dismal outcome. Treatment options for these patients are limited primarily due to the paucity of effective therapeutics. Immune therapies such as tumor vaccines and traditional antigen-targeted monoclonal antibodies have had limited success in solid tumors. The recent discovery of novel immune checkpoint blockade strategies and their success in adult cancers has revitalized the use of immunotherapy strategies for the treatment of solid tumors. This paper summarizes existing data supporting the use of immune therapies in osteosarcoma and the progress of this class of drugs in osteosarcoma therapy.

引用

页码：1233 / 1244

页数：12

共 99 条

[1] Regulatory T cells in cancer; can they be controlled? [J].

Adeegbe, Dennis O. ;

Nishikawa, Hiroyoshi .

IMMUNOTHERAPY, 2015, 7 (08) :843-846

[2] Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody [J].

Ahmed, Mahiuddin ;

Cheng, Ming ;

Cheung, Irene Y. ;

Cheung, Nai-Kong V. .

ONCOIMMUNOLOGY, 2015, 4 (04)

[3] Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma [J].

Ahmed, Nabil ;

Brawley, Vita S. ;

Hegde, Meenakshi ;

Robertson, Catherine ;

Ghazi, Alexia ;

Gerken, Claudia ;

Liu, Enli ;

Dakhova, Olga ;

Ashoori, Aidin ;

Corder, Amanda ;

Gray, Tara ;

Wu, Meng-Fen ;

Liu, Hao ;

Hicks, John ;

Rainusso, Nino ;

Dotti, Gianpietro ;

Mei, Zhuyong ;

Grilley, Bambi ;

Gee, Adrian ;

Rooney, Cliona M. ;

Brenner, Malcolm K. ;

Heslop, Helen E. ;

Wels, Winfried S. ;

Wang, Lisa L. ;

Anderson, Peter ;

Gottschalk, Stephen .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15) :1688-+

[4] Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression [J].

Ahmed, Nabil ;

Salsman, Vita S. ;

Yvon, Eric ;

Louis, Chrystal U. ;

Perlaky, Laszlo ;

Wels, Winfried S. ;

Dishop, Meghan K. ;

Kleinerman, Eugenie E. ;

Pule, Martin ;

Rooney, Cliona M. ;

Heslop, Helen E. ;

Gottschalk, Stephen .

MOLECULAR THERAPY, 2009, 17 (10) :1779-1787

[5] Mifamurtide for the treatment of nonmetastatic osteosarcoma [J].

Ando, Kosei ;

Mori, Kanji ;

Corradini, Nedege ;

Redini, Francoise ;

Heymann, Dominique .

EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (02) :285-292

[6]

[Anonymous], 2015, ONCOLOGY TIMES

[7]

Bacci G, 2000, ONCOL REP, V7, P339

[8] Tumor regression in cancer patients by very low doses of a T cell-engaging antibody [J].

Bargou, Ralf ;

Leo, Eugen ;

Zugmaier, Gerhard ;

Klinger, Matthias ;

Goebeler, Mariele ;

Knop, Stefan ;

Noppeney, Richard ;

Viardot, Andreas ;

Hess, Georg ;

Schuler, Martin ;

Einsele, Hermann ;

Brandl, Christian ;

Wolf, Andreas ;

Kirchinger, Petra ;

Klappers, Petra ;

Schmidt, Margit ;

Riethmueller, Gert ;

Reinhardt, Carsten ;

Baeuerle, Patrick A. ;

Kufer, Peter .

SCIENCE, 2008, 321 (5891) :974-977

[9] Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment [J].

Beatty, Gregory L. ;

Moon, Edmund K. .

ONCOIMMUNOLOGY, 2014, 3 (11) :e970027-1

[10] Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer [J].

Bendell, Johanna ;

Saleh, Mansoor ;

Rose, April A. N. ;

Siegel, Peter M. ;

Hart, Lowell ;

Sirpal, Surendra ;

Jones, Suzanne ;

Green, Jennifer ;

Crowley, Elizabeth ;

Simantov, Ronit ;

Keler, Tibor ;

Davis, Thomas ;

Vahdat, Linda .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (32) :3619-+

← 1 2 3 4 5 6 7 8 9 10 →